

**CURRENT STATUS OF CLAIMS WITH CLAIM AMENDMENTS**

1-20. (Canceled)

21. (Presently amended) A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:

(a) obtaining a sample from said individual;

(b) measuring a test expression level of PAMP polypeptide by contacting a cell, a cell lysate, or fractionated sample thereof, from said individual with a binding agent selective for [PAMP polypeptide] residues 1 to 1074 of **a PAMP polypeptide comprising the amino acid sequence shown as SEQ ID NO: 2 or an amino acid sequence having one or more conservative substitutions relative to** SEQ ID NO:2, and determining the amount of selective binding of said agent; and

(c) comparing said test expression level of PAMP polypeptide to a control expression level of PAMP polypeptide,

wherein a test expression level **significantly** [2-fold or more] greater than said control expression level indicates the presence of a prostate neoplastic condition.

22. (Presently amended) The method of claim 21, wherein said binding agent [selective for said PAMP polypeptide residues 1 to 1074 of SEQ ID NO: 2] comprises an antibody.

23. **(Withdrawn)** The method of claim 22, wherein said binding agent further comprises a detectable label.

24-25. **(Canceled)**

26. **(Previously presented)** An isolated PAMP polypeptide, comprising the amino acid sequence shown as SEQ ID NO: 2 or an amino acid sequence having one or more conservative substitutions relative to SEQ ID NO: 2.

27. **(Previously presented)** The isolated PAMP polypeptide of claim 26, comprising the amino acid sequence shown as SEQ ID NO:2.

28-29. **(Canceled)**

30. **(Withdrawn)** The method of claim 21, wherein said binding agent is a monoclonal antibody.

31. **(Withdrawn)** The method of claim 21, wherein said binding agent is a polyclonal antibody.

32. **(Withdrawn)** The method of claim 21, wherein said sample is a serum sample.